I was having a conversation off of here, but thoug
Post# of 36537
The Chinese firm that Generex / NGIO has been working with in the past has put in a bid for NGIO and this brought up an interesting point.
With the huge virus issue currently going on over in China along with the bird flu and possible other issues, the bid actually makes sense and purchasing NGIO at a low bid, they would turn a pretty hefty profit in the long run.
Then I believe they would also get the wound care as well. Please correct me if I am wrong here. With all that is going on in the war between Russia and Ukraine and from all reports, this is going to drag on for a long time and even after, China has a strong relationship with Russia, the wound care product would also be a huge deal with Russia for years to come, along with any confrontation China has with Taiwan. So, they might be looking at a long term plan here.
Purchasing a small company to get the needed information. Whether they bring it to the market or not is the bigger question. Do, they bring it to Nasdaq or not? What do they do? Or does the bidder bid more?
Also, what impact will any of this have on shareholders?